<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310215</url>
  </required_header>
  <id_info>
    <org_study_id>CARTISTEM_2019_01</org_study_id>
    <nct_id>NCT04310215</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus</brief_title>
  <official_title>A Multi-center, Single-blind, Randomized, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adding CARTISTEM® on Microfracture in Patients With Talar Chondral or Osteochondral Defect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK bioland co., ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medipost Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SK bioland co., ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of adding
      CARTISTEM®(allogenic umbilical cord blood-derived stem cell product) on microfracture, a
      currently standard treatment for OLT, in patients with talar chondral or osteochondral
      defect.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicenter, Single-blinded, Stratified randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICRS-Cartilage Repair Assessment Total Score</measure>
    <time_frame>Week 48</time_frame>
    <description>Arthroscopic evaluation of articular cartilage repair
: The score range from 12(normal) to 1(severely abnormal) where lower scores indicate more severity of injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICRS-Cartilage Repair Assessment Overall Grade</measure>
    <time_frame>Week 48</time_frame>
    <description>The grades range from 1(normal) to 4 (severely abnormal) where lower grades indicate more complete repair</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement degree of Cartilage Repair by MRI</measure>
    <time_frame>Week 0 and 48</time_frame>
    <description>Changes in MOCART(Magnetic resonance Observation of Cartilage Repair Tissue) score
: MOCART score is a 9-part and 29-item scoring system, also resulting in a find cartilage repair tissue score between 0 and 100 points. 100 points represent the best imaginable score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Functional improvement in FAOS(Foot &amp; Ankle Outcome Score)</measure>
    <time_frame>Week 0, 24 and 48</time_frame>
    <description>: FAOS consists in 42 items that cover 5 dimensions (symptoms, pain, activities of daily living, sport and recreation activities, and quality of life. Raw scores of each sub-scales results of the sum of each items. A normalized score (100 indicationg no symptoms and 0 indicating extreame sysmptoms) is calculated for each subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Functional improvement in AOFAS(The American Orthopaedic Foot &amp; Ankle Score)</measure>
    <time_frame>Week 0, 24 and 48</time_frame>
    <description>: AOFAS consists in 9 items that can be divided into 3 sub-scales (pain, function and alignment). 100 points of 1 to 100 represent no symptoms or impairments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Functional improvement in Tegner activity score</measure>
    <time_frame>Week 0, 24 and 48</time_frame>
    <description>: Tegner activity represents the highest level of activity on scale of 0 to 10 that you are able to participate in currently . The higher values represent a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36)</measure>
    <time_frame>Week 0, 24 and 48</time_frame>
    <description>: SF-36 comprises 36 items divided into two components of physical health and mental health. Higher scores between 0 and 100 represent better health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of pain improvement in 100 mm VAS(Visual Analogue Scale)</measure>
    <time_frame>Week 0, 24 and 48</time_frame>
    <description>VAS represents higher scores mean higher pain
0 mm (no pain) and 100 mm (worst pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chondral or Osteochondral Lesion of Talus</condition>
  <arm_group>
    <arm_group_label>Microfracture + CARTISTEM®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CARTISTEM® is added on the lesion as a single dose of 500 ㎕/㎠ according to the defect size after arthroscopic curettage and microfracture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microfracture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment of arthroscopic curettage and microfracture is performed for cartilage defect.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CARTISTEM®</intervention_name>
    <description>*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠
Procedure: Microfracture
Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)</description>
    <arm_group_label>Microfracture + CARTISTEM®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microfracture</intervention_name>
    <description>*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠
1. Procedure: Microfracture</description>
    <arm_group_label>Microfracture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. No response to conservative treatment for more than 12 weeks, talar
             chondral/osteochondral lesion radiographically confirmed by MRI, ankle joint
             pain/stiffness and an AOFAS score of 75 or below

          2. Ankle joint cartilage injury of defect of ICRS grade Ⅳ

          3. Male or female aged between 20 to 70

          4. A one-sided lesion

          5. Appropriate function of blood clot: PT(INR) &lt; 1.5×ULN, aPTT &lt;1.5×ULN

          6. Appropriate renal function: Creatinine ≤ 2.0 ㎎/㎗, Proteinuria ≤ trace

          7. Appropriate hepatic function: Total bilirubin ≤ 2.0 ㎎/㎗, AST/ALT ≤ 100 IU/L

          8. No evidence of auto-immune disorder: Anti-nuclear antibody and anti-thyroglobulin
             antibody negative (If positive, there are possible case according to rheumatologist's
             diagnostic opinion)

          9. No surgery or radiotherapy for the same ankle joint within 6 weeks

         10. Female patients agreeing with maintenance of contraception* during study period

             *hormone contraceptive, implants of intrauterine device or intrauterine system, double
             barrier contraception[Concurrent use of diaphragm or cervical occlusive cap and male
             condom], surgical sterilisation, etc.

         11. No chronic ligament instability more than grade Ⅲ (Grade 0: none, Grade Ⅰ: 1~5㎜,
             GradeⅡ: 5~10㎜, Grade Ⅲ: &gt;10㎜)

         12. Patients agreeing with participation in this study and signed on informed consent by
             their own will

        Exclusion Criteria:

          1. Degenerative arthritis in ankle(Kellgren Lawrence Grade 3-4)

          2. Autoimmune disease

          3. Infectious disease need to administration of parenteral antibiotics

          4. Myocardial infarction, congestive heart failure, other serious cardiac disorder or
             uncontrolled resistant hypertension

          5. Serious medical disease(Ex. Kidney disease such as chronic renal failure or
             Glomerulonephritis, etc., acute/chronic liver disease such as liver cirrhosis, fatty
             liver etc., medical history of malignancy*)

             *Complete remission status is possible.

          6. Pregnancy or breast-feeding

          7. Psychiatric history or epilepsy

          8. Alcohol abuse

          9. Heavy smoker

         10. Chronic inflammatory disease such as rheumatoid arthritis

         11. Participants other clinical trials within 4 weeks

         12. Administration of immunosuppressing agents such as Cyclosporin A or azathioprine
             within 6 weeks

         13. Patients with acute ligament injury and clinically significant chronic ligament
             instability

         14. Patients treated with surgery or cell therapy product for the same disease

         15. Patients with hypersensitivity or allergy history to bovine protein, hyaluronic acid
             and gentamicin

         16. Other inappropriate patients determined by the principal investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyunghee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Dongdaemun-gu</state>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro-gu</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Jung-gu</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Jung-gu</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OLT</keyword>
  <keyword>Talus</keyword>
  <keyword>Chondral Lesion</keyword>
  <keyword>Osteochondral Lesion</keyword>
  <keyword>Human umbilical cord blood-derived stem cell</keyword>
  <keyword>MSC</keyword>
  <keyword>Mesenchymal stem cell</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

